according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

#### **SECTION 1. IDENTIFICATION**

Product name : Ertugliflozin (< 5%) / Sitagliptin Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

# GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Skin irritation : Category 2

Serious eye damage : Category 1

Skin sensitization : Category 1

Specific target organ toxicity

- repeated exposure (Oral)

Category 2 (Kidney, Stomach, Prostate)

**GHS** label elements

Hazard pictograms :







Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H315 Causes skin irritation.

H317 May cause an allergic skin reaction. H318 Causes serious eye damage.

H373 May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P260 Do not breathe dust.

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

P264 Wash skin thoroughly after handling.

P272 Contaminated work clothing must not be allowed out of the workplace.

P280 Wear protective gloves, eye protection and face protec-

tion.

#### Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON

P314 Get medical attention if you feel unwell.

P333 + P313 If skin irritation or rash occurs: Get medical atten-

tion.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

#### Other hazards

None known.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

## Components

Chemical name	CAS-No.	Concentration (% w/w)
Sitagliptin	654671-77-9	>= 30 - < 50
Cellulose	9004-34-6	>= 20 - < 30
Ertugliflozin	1210344-83-4	>= 1 - < 5
Magnesium stearate	557-04-0	>= 1 - < 5
Propyl 3,4,5-trihydroxybenzoate	121-79-9	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention.
Wash clothing before reuse.

Thoroughly clean shoes before reuse.

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 03/06/2023 09/30/2023 2400342-00013 Date of first issue: 02/01/2018 5.1

In case of contact, immediately flush eyes with plenty of water In case of eye contact

for at least 15 minutes.

If easy to do, remove contact lens, if worn. Get medical attention immediately.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water. Causes skin irritation. Most important symptoms

and effects, both acute and

delayed

May cause an allergic skin reaction.

Causes serious eye damage.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

First Aid responders should pay attention to self-protection. Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Metal oxides

Oxides of phosphorus

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec: : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation. Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Do not swallow.

Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

#### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

# Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 mg/m<sup>3</sup>

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m<sup>3</sup>

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

ticulates

10 mg/m<sup>3</sup>

Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

5 mg/m<sup>3</sup>

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sitagliptin	654671-77-9	TWA	0.5 mg/m3 (OEB 2)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m³	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m³	OSHA Z-1
Ertugliflozin	1210344-83- 4	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH

#### **Engineering measures**

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices).

Minimize open handling.

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

## Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

## **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials
Hazardous decomposition

Hazardous decompositior

products

No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

## Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

**Components:** 

Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

LD50 (Mouse): 3,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Ertugliflozin:** 

Acute oral toxicity : LD50 (Rat): 500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Magnesium stearate:

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icitv

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:** 

Acute oral toxicity : LD50 (Mouse, female): > 1,000 - 2,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Causes skin irritation.

**Components:** 

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

**Ertugliflozin:** 

Result : Corrosive

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:** 

Species : reconstructed human epidermis (RhE)

Method : OECD Test Guideline 439

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

**Components:** 

Sitagliptin:

Species : Rabbit

Result : Irritating to eyes. Method : Draize Test

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

**Ertugliflozin:** 

Result : Severe irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Species : Rabbit

Result : Irreversible effects on the eye Method : OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Not classified based on available information.

**Components:** 

Sitagliptin:

Test Type : Local lymph node assay (LLNA)

Species : Mouse

Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

**Ertugliflozin:** 

Test Type : Local lymph node assay (LLNA)

Result : Not a skin sensitizer.

Magnesium stearate:

Test Type : Maximization Test Routes of exposure : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact
Species : Mouse
Result : positive

Assessment : Probability or evidence of skin sensitization in humans

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: 5.1 09/30/2023

SDS Number: 2400342-00013

Date of last issue: 03/06/2023 Date of first issue: 02/01/2018

#### Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

**Ertugliflozin:** 

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

## **Propyl 3,4,5-trihydroxybenzoate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: positive

Test Type: Chromosome aberration test in vitro

Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Test Type: In vitro sister chromatid exchange assay in mam-

malian cells Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

## Carcinogenicity

Not classified based on available information.

## **Components:**

## Sitagliptin:

Species: MouseApplication Route: OralExposure time: 2 YearsResult: negative

Species : Rat

Application Route : oral (drinking water)

Exposure time : 2 Years
Result : positive
Target Organs : Liver

Remarks : Significant toxicity observed in testing

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

**Ertugliflozin:** 

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

## Propyl 3,4,5-trihydroxybenzoate:

Species : Rat
Application Route : Ingestion
Exposure time : 103 weeks
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA**No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

## Reproductive toxicity

Not classified based on available information.

# Components:

Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Parent: 1,000 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit

Teratogenicity: NOAEL: 125 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

**Application Route: Ingestion** 

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

**Ertugliflozin:** 

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight Remarks: Maternal toxicity observed. No significant adverse effects were reported

Test Type: Fertility/early embryonic development

Species: Rabbit Application Route: Oral

Fertility: NOAEL: 200 mg/kg body weight

Remarks: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 250 mg/kg body weight Remarks: No significant adverse effects were reported

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

reproduction/developmental toxicity screening test

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:** 

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

**Application Route: Ingestion** 

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

**Components:** 

**Ertugliflozin:** 

Routes of exposure : Oral

Target Organs : Kidney, Stomach, Prostate

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

**Components:** 

Sitagliptin:

Species : Mouse
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg

Application Route : Oral
Exposure time : > 2 y
Target Organs : Kidney

 Species
 : Rat

 NOAEL
 : 500 mg/kg

 LOAEL
 : 1,000 mg/kg

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Application Route : Oral Exposure time : 14 Weeks

Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks

Target Organs : Skeletal muscle, Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg Application Route : Ingestion

Exposure time : 90 Days

**Ertugliflozin:** 

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat

LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Target Organs : Kidney, Bone, Stomach

Species : Rat LOAEL : 25 mg/kg Exposure time : 90 d

Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog NOAEL : 150 mg/kg Application Route : Oral Exposure time : 270 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone

Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:** 

Species : Rat
NOAEL : 135 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

**Aspiration toxicity** 

Not classified based on available information.

Experience with human exposure

**Components:** 

Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis,

Headache

Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis,

Headache, Nausea, Abdominal pain, Diarrhea

**Ertugliflozin:** 

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Ingestion : Symptoms: The most common side effects are:, Headache,

constipation, Diarrhea, Nausea, urinary tract infection, muscle

pain, upper respiratory tract infection

#### **SECTION 12. ECOLOGICAL INFORMATION**

## **Ecotoxicity**

#### Components:

Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 60 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 39

mg/

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 150 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

#### **Ertugliflozin:**

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 2.14 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 19.06 mg/l

Exposure time: 48 h

Test substance: Neutralized product Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.37

mg/l

Exposure time: 72 h

Test substance: Neutralized product Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): 0.17

mg/l

Exposure time: 72 h

Test substance: Neutralized product Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: 636 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Persistence and degradability

**Components:** 

Sitagliptin:

Biodegradability : Result: not rapidly degradable

Biodegradation: 39.7 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)

Method: OECD Test Guideline 111

Cellulose:

Biodegradability : Result: Readily biodegradable.

**Ertugliflozin:** 

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 40.8 % Exposure time: 28 d

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

Propyl 3,4,5-trihydroxybenzoate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 49.4 % Exposure time: 28 d

Method: OECD Test Guideline 301F

**Bioaccumulative potential** 

Components:

Sitagliptin:

Partition coefficient: noctanol/water log Pow: -0.03

otario, mator

Ertugliflozin:

Partition coefficient: n-

: log Pow: 2.47

octanol/water

Magnesium stearate:

Partition coefficient: n-

log Pow: > 4

octanol/water

Propyl 3,4,5-trihydroxybenzoate:

Partition coefficient: n- : log Pow: 1.8

octanol/water Remarks: Calculation

Mobility in soil

**Components:** 

Sitagliptin:

Distribution among environ-

: log Koc: 4.37

mental compartments

**Ertugliflozin:** 

Distribution among environ-

: log Koc: 2.88

mental compartments

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

#### **IMDG-Code**

Not regulated as a dangerous good

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **Domestic regulation**

#### **49 CFR**

Not regulated as a dangerous good

#### Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

## **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Respiratory or skin sensitization

Specific target organ toxicity (single or repeated exposure)

Skin corrosion or irritation

Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## **US State Regulations**

## Pennsylvania Right To Know

Sitagliptin 654671-77-9
Cellulose 9004-34-6
Calcium hydrogenorthophosphate 7757-93-9
Ertugliflozin 1210344-83-4

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

Sodium octadecyl fumarate 4070-80-8

#### California Permissible Exposure Limits for Chemical Contaminants

Cellulose 9004-34-6 Magnesium stearate 557-04-0

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

#### **Further information**

#### NFPA 704:

# Flammability Health 3 O Instability

Special hazard

#### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8, Article 107)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average CAL PEL / PEL : Permissible exposure limit

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average OSHA Z-3 / TWA : 8-hour time weighted average

according to the OSHA Hazard Communication Standard



# Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/06/2023 5.1 09/30/2023 2400342-00013 Date of first issue: 02/01/2018

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8